|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2, Open-label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.
/ RecruitingEarly Phase 1IIT A Single-Arm, Open-Label, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 Injection in Patients with Duchenne Muscular Dystrophy
The purpose of the study is to assess the safety, tolerability, and efficacy of BBM-D101 to treat patients with Duchenne Muscular Dystrophy.
100 Clinical Results associated with Shanghai Mianyi Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shanghai Mianyi Biopharmaceutical Co., Ltd.
100 Deals associated with Shanghai Mianyi Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Shanghai Mianyi Biopharmaceutical Co., Ltd.